Can a patient concurrently initiate a new selective serotonin reuptake inhibitor (SSRI) and undergo ketamine infusions?

Concurrent Initiation of SSRI and Ketamine Infusions

Yes, a patient can concurrently start a new SSRI and undergo ketamine infusions—in fact, this combination is explicitly supported by current evidence and is the FDA-approved approach for esketamine. 1

Evidence-Based Framework

Guideline Support for Combination Therapy

The 2022 VA/DoD guidelines for major depressive disorder recommend ketamine or esketamine specifically as augmentation therapy in treatment-resistant depression (TRD), meaning it is designed to be used alongside ongoing antidepressant treatment 2. The evidence base demonstrates that:

• Ketamine added to ongoing antidepressant treatment showed significant improvements in depressive symptoms for up to 7 days in TRD patients 2
• Esketamine is FDA-approved exclusively in combination with an SSRI or SNRI, not as monotherapy 1
• Meta-analysis of 5 RCTs found that esketamine as augmentation to ongoing oral antidepressants improved depressive symptoms and remission rates at 28-day follow-up 2

Real-World Evidence for Starting Both Concurrently

A recent large-scale comparative effectiveness study (2025) examined 55,480 patients with TRD treated with esketamine combined with either SSRIs or SNRIs 3. This demonstrates that initiating both treatments together is standard clinical practice. The study found:

• Low overall incidence of adverse events across both combinations
• Both esketamine + SSRI and esketamine + SNRI combinations were safe and effective
• Esketamine + SNRI showed slightly lower mortality, hospitalization, and relapse rates
• Esketamine + SSRI showed marginally lower suicide attempt rates

Specific Clinical Context: New SSRI Initiation

One randomized controlled trial specifically addressed your exact question: 30 patients with MDD were randomized to ketamine infusion plus newly initiated escitalopram versus placebo infusion plus escitalopram 4. The ketamine/escitalopram group showed:

• Lower suicidal ideation scores from 1 to 72 hours post-treatment
• Effect sizes ranging from 1.05 to 2.24 during this period
• Patients were medication-free except for the concomitant initiation of escitalopram on the first treatment day

This directly demonstrates the safety and efficacy of starting both treatments simultaneously.

Safety Considerations

Serotonin Syndrome Risk

While theoretically concerning, serotonin syndrome with ketamine and SSRIs is extremely rare. The evidence shows:

• Only one case report exists of serotonin syndrome involving ketamine, and this occurred in the context of ECT (electroconvulsive therapy) combined with ketamine in a patient already on serotonergic medications 5
• The FDA drug label for ketamine does not list SSRIs as contraindicated or requiring special precautions 6
• Systematic review of pharmacodynamic interactions found no significant safety signals between ketamine and SSRIs/SNRIs 7

Clinical caveat: The single case report involved ECT + ketamine + existing serotonergic medications, representing a unique high-risk scenario. Standard ketamine infusions with SSRIs do not carry this documented risk 5.

Drug Interactions to Monitor

The FDA label identifies relevant interactions, but SSRIs are not among them 6:

• Benzodiazepines: May reduce duration of ketamine's antidepressant effect 7—consider avoiding or minimizing during ketamine treatment
• CNS depressants: Risk of profound sedation (relevant for opioids, not SSRIs)
• No specific warnings regarding SSRIs or SNRIs

Practical Implementation Algorithm

For patients with treatment-resistant depression:

1. Confirm TRD criteria: At least 2 adequate trials of antidepressants have failed 2

2. Initiate SSRI or SNRI (if starting new antidepressant):

   • Esketamine requires concurrent SSRI/SNRI per FDA approval 1
   • For IV ketamine: combination is supported but not mandated

3. Begin ketamine/esketamine protocol:

   • Esketamine: Twice-weekly intranasal dosing with mandatory 2-hour monitoring 2
   • IV ketamine: 0.5 mg/kg over 40 minutes, typically 2-3 times weekly 2

4. Monitor for:

   • Standard ketamine side effects (dissociation, blood pressure elevation)
   • SSRI side effects (nausea, activation, sexual dysfunction)
   • Not serotonin syndrome (no evidence base for routine concern)

5. Avoid concurrent benzodiazepines if possible, as they may attenuate ketamine's antidepressant effects 7

Duration and Maintenance

• Ketamine effects are typically transient (days to 1 week) 2
• The SSRI provides the foundation for longer-term maintenance
• Repeated ketamine infusions may be needed to sustain benefit
• Evidence supports this combination approach for up to 28 days and beyond 2

Bottom line: Not only is it safe to start an SSRI and ketamine concurrently, but for esketamine this combination is the only FDA-approved approach, and the evidence base specifically supports initiating both treatments together in treatment-resistant depression.